相似文献
1
In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.
J Clin Microbiol. 2014 Nov;52(11):4049-52. doi: 10.1128/JCM.02357-14. Epub 2014 Aug 20.
2
Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Antimicrob Agents Chemother. 2014;58(4):2434-7. doi: 10.1128/AAC.02398-13. Epub 2014 Jan 21.
3
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
J Infect. 2014 Sep;69(3):266-77. doi: 10.1016/j.jinf.2014.04.004. Epub 2014 Apr 26.
4
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
Antimicrob Agents Chemother. 2013 Dec;57(12):6305-10. doi: 10.1128/AAC.01802-13. Epub 2013 Oct 7.
5
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.
6
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Int J Antimicrob Agents. 2015 Nov;46(5):502-10. doi: 10.1016/j.ijantimicag.2015.07.004. Epub 2015 Aug 10.
7
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.
8
Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00160-19. Print 2019 Jul.
9
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.
10
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.
引用本文的文献
1
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Ann Intensive Care. 2023 Feb 11;13(1):8. doi: 10.1186/s13613-022-01084-8.
2
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):51-53. doi: 10.37201/req/s03.12.2022. Epub 2022 Oct 24.
3
A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies.
Open Forum Infect Dis. 2022 Feb 14;9(6):ofac079. doi: 10.1093/ofid/ofac079. eCollection 2022 Jun.
4
Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Antimicrob Agents Chemother. 2022 May 17;66(5):e0139921. doi: 10.1128/aac.01399-21. Epub 2022 Apr 26.
5
Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.
Braz J Infect Dis. 2020 Mar-Apr;24(2):96-103. doi: 10.1016/j.bjid.2020.04.004. Epub 2020 Apr 28.
6
Ceftolozane/Tazobactam Susceptibility Testing in Extended-Spectrum Betalactamase- and Carbapenemase-Producing Gram-Negative Bacteria of Various Clonal Lineages.
Eur J Microbiol Immunol (Bp). 2019 Feb 8;9(1):1-4. doi: 10.1556/1886.2019.00001. eCollection 2019 Mar 18.
7
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
Med Sci Monit. 2019 Jan 10;25:305-311. doi: 10.12659/MSM.913352.
8
Production of β-Lactamase Inhibitors by Species.
Antibiotics (Basel). 2018 Jul 17;7(3):61. doi: 10.3390/antibiotics7030061.
9
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
Ann Lab Med. 2017 Mar;37(2):174-176. doi: 10.3343/alm.2017.37.2.174.
10
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.
Ther Clin Risk Manag. 2016 Dec 1;12:1811-1826. doi: 10.2147/TCRM.S120811. eCollection 2016.
本文引用的文献
1
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Int J Antimicrob Agents. 2014 Jun;43(6):533-9. doi: 10.1016/j.ijantimicag.2014.01.032. Epub 2014 Mar 26.
2
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.
Antimicrob Agents Chemother. 2014;58(2):833-8. doi: 10.1128/AAC.01896-13. Epub 2013 Nov 18.
3
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.
Antimicrob Agents Chemother. 2013 Aug;57(8):4010-8. doi: 10.1128/AAC.02516-12. Epub 2013 Jun 10.
4
A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China.
J Med Microbiol. 2013 Sep;62(Pt 9):1343-1349. doi: 10.1099/jmm.0.059816-0. Epub 2013 Jun 5.
5
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.
6
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
Int J Infect Dis. 2013 Aug;17(8):e638-43. doi: 10.1016/j.ijid.2013.01.030. Epub 2013 Mar 21.
7
Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.
PLoS One. 2013;8(2):e56926. doi: 10.1371/journal.pone.0056926. Epub 2013 Feb 21.
8
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Antimicrob Agents Chemother. 2013 Apr;57(4):1577-82. doi: 10.1128/AAC.01590-12. Epub 2012 Dec 28.
9
Clonal structure, extended-spectrum β-lactamases, and acquired AmpC-type cephalosporinases of Escherichia coli populations colonizing patients in rehabilitation centers in four countries.
Antimicrob Agents Chemother. 2013 Jan;57(1):309-16. doi: 10.1128/AAC.01656-12. Epub 2012 Oct 31.
10
Characterization of fluoroquinolone and cephalosporin resistance mechanisms in Enterobacteriaceae isolated in a Dutch teaching hospital reveals the presence of an Escherichia coli ST131 clone with a specific mutation in parE.
J Antimicrob Chemother. 2013 Jan;68(1):40-5. doi: 10.1093/jac/dks365. Epub 2012 Sep 18.
Zotero 插件